JRVR earnings analysis
What we found in JRVR's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
JRVR delivered $161.344 million of Q2 revenue and diluted EPS of $0.10, with net income improving year over year and the E&S segment remaining profitable. However, premium volumes contracted sharply, Specialty Admitted Insurance deteriorated, and the consolidated combined ratio exceeded 100%, resulting in a $327,000 underwriting loss. Liquidity weakened with cash falling by $65.365 million during the first six months, while the exhausted $75.0 million E&S Top Up ADC and less-than-3% goodwill cushion add material downside risks.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue recovered sequentially; EPS improved
- Total revenue was $161.344 million, up from $151.0 million in the prior quarter but down 7.7% from $174.843 million a year earlier. Diluted EPS was $0.10, improving from a $0.23 loss in Q1 2026 and from $0.06 in Q2 2025.
- Net income improved year over year
- Net income from continuing operations increased 29.3% year over year to $6.620 million from $5.120 million, while net income available to common shareholders rose 58.8% to $4.430 million from $2.790 million.
- E&S underwriting remained profitable
- The Excess & Surplus Lines segment remained profitable with $9.929 million of underwriting profit and a 92.8% combined ratio, despite gross written premiums declining 16.7% to $250.170 million.
- Expense reductions continued
- General and administrative expenses declined by $2.5 million year over year, including a $2.3 million reduction in Specialty Admitted Insurance expenses. Corporate and Other operating expenses decreased to $7.449 million from $8.222 million.
- Investment income supported results
- Net investment income increased 2.7% year over year to $41.604 million for the first six months, driven by higher income from fixed maturities and structured private credit investments.
- Investment portfolio remained investment grade
- The fixed-maturity portfolio totaled $1.439 billion at fair value, and 100.0% of the portfolio was rated BBB- or better. Management recorded no credit-related impairments on fixed maturities at June 30, 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Specialty Admitted volume contracted
- The Specialty Admitted Insurance segment’s gross written premiums fell 75.9% year over year to $18.729 million, and its underwriting loss widened to $2.807 million from $1.421 million. Management attributed the decline to program non-renewals; the segment currently has four active programs.
- Consolidated underwriting turned unprofitable
- The consolidated combined ratio increased to 100.2% from 98.6% a year earlier, producing a $327,000 underwriting loss versus a $2.064 million underwriting profit. The expense ratio rose to 33.9% from 30.5% as net earned premiums declined 8.9%.
- Retroactive reinsurance limit exhausted
- The E&S Top Up ADC had a $75.0 million aggregate limit, and the company disclosed that none remained available as of June 30, 2026 after $23.6 million of additional adverse development was ceded during the first six months.
- Liquidity declined during the period
- Cash and cash equivalents declined to $195.576 million from $260.941 million at December 31, 2025, while six-month operating cash flow excluding restricted cash was negative $5.926 million and investing cash flow was negative $53.839 million.
- Reinsurance availability and protection risk
- The company added a risk-factor update stating that reinsurance may become unavailable or uneconomic; the E&S Top Up ADC’s $75.0 million limit was fully exhausted, potentially increasing exposure to adverse loss development.
- Goodwill impairment cushion is narrow
- Goodwill impairment testing showed the E&S reporting unit’s fair value exceeded carrying value by less than 3% at June 30, 2026, after a substantial decline in stock price and market capitalization. Further adverse conditions could result in impairment of the $181.831 million goodwill balance.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.1
- Segment
- Excess & Surplus Lines: gross written premiums $250.170 million, down 16.7% year over year; net earned premiums $137.306 million, down 2.9%; underwriting profit $9.929 million versus $11.707 million.
- Segment
- Specialty Admitted Insurance: gross written premiums $18.729 million, down 75.9% year over year; net earned premiums $1.712 million, down 84.8%; underwriting loss $2.807 million versus $1.421 million.
- Segment
- Corporate and Other: operating expenses $7.449 million versus $8.222 million.
What they said about what is next.
No quantitative revenue or EPS guidance was provided in the 10-Q; management stated that quarterly results are not necessarily indicative of the full year. The A.M. Best rating remained A- (Excellent) with a negative outlook.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 5, 2026
- James River Group Holdings, Inc. reported disappointing Q1 2026 results with revenues of $135.71 million, missing estimates by 18.35%, and earnings per share (EPS) of $0.12, falling short of estimates by 57.14%. A net…
- 10-K · April 30, 2026
- James River Group Holdings, Inc. (JRVR) reported challenging financial results for 2025, primarily missing consensus estimates for both revenue and EPS in Q4. The company is refocusing its strategic objectives towards…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing JRVR makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever